organization · Reporting owner

FMR LLC

Disclosed activity across 29 companies

Tapewire entity: 28868
SEC CIK: 0000315066

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Avalyn Pharma Inc.AVLN · Entity 4662	10% owner · See Remark 1	May 01, 2026	May 05, 2026
Beam Therapeutics Inc.BEAM · Entity 4227	10% owner · See Remark 1	June 25, 2026	June 29, 2026
Fidelity Multi-Strategy Credit FundNONE · Entity 74426	10% owner · See Remark 1	May 19, 2023	May 26, 2023
Rallybio CorpRLYB · Entity 6838	10% owner · See Remark 1	March 04, 2026	March 10, 2026
Sana Biotechnology, Inc.SANA · Entity 4870	10% owner · See Remark 1	January 08, 2025	January 10, 2025
Structure Therapeutics Inc.GPCR · Entity 1222	10% owner · See Remark 1	July 22, 2026	July 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Avalyn Pharma Inc.

Report date May 01, 2026 · Filed May 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	727,585	Reported balance After 2026-05-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-05-01 · Conversion · Acquired 727,585 · Balance 727,585 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	807,876	Reported balance After 2026-05-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-05-01 · Conversion · Acquired 80,291 · Balance 807,876 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	1,680,744	Reported balance After 2026-05-01 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-05-01 · Conversion · Acquired 872,868 · Balance 1,680,744 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	1,906,587	Reported balance After 2026-05-01 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-05-01 · Conversion · Acquired 225,843 · Balance 1,906,587 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	2,284,535	Reported balance After 2026-05-01 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-05-01 · Conversion · Acquired 377,948 · Balance 2,284,535 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund V LP	0	Reported balance After 2026-05-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-01 · Conversion · Disposed 727,585 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund V LP	0	Reported balance After 2026-05-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-01 · Conversion · Disposed 80,291 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series C-1 Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund V LP	0	Reported balance After 2026-05-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-05-01 · Conversion · Disposed 872,868 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series C-2 Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund V LP	0	Reported balance After 2026-05-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-01 · Conversion · Disposed 225,843 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund V LP	0	Reported balance After 2026-05-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-05-01 · Conversion · Disposed 377,948 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

Beam Therapeutics Inc.

Report date June 25, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	1,106,071	Reported balance After 2026-06-25 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-06-25 · Sale · Disposed 33,372 · Balance 1,106,071 F1: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.39. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	854,583	Reported balance After 2026-06-26 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-06-26 · Sale · Disposed 251,488 · Balance 854,583 F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Common StockSEC Table I · non-derivative	IndirectFMR Capital, Inc.	14	Reported balance Holding disclosure · report date 2026-06-25 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 14
Common StockSEC Table I · non-derivative	IndirectShares held by persons and entities whose shares are subject to reporting by the undersigned.	841,231	Reported balance Holding disclosure · report date 2026-06-25 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 841,231

Filing footnotes · ownership attribution and instrument terms

F1: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.39. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Fidelity Multi-Strategy Credit Fund

Report date May 19, 2023 · Filed May 26, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares of Beneficial OwnershipSEC Table I · non-derivative	Direct	2,500,000	Reported balance Holding disclosure · report date 2023-05-19 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,500,000

Rallybio Corp

Report date March 04, 2026 · Filed March 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	211,798	Reported balance Holding disclosure · report date 2026-03-04 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 211,798

Sana Biotechnology, Inc.

Report date January 08, 2025 · Filed January 10, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	4,732,423	Reported balance After 2025-01-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-01-08 · Sale · Disposed 100,000 · Balance 4,732,423 F1: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.05 to $6.24. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	4,707,423	Reported balance After 2025-01-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-01-08 · Sale · Disposed 25,000 · Balance 4,707,423 F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.50 to $6.55. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	4,542,511	Reported balance After 2025-01-08 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2025-01-08 · Sale · Disposed 164,912 · Balance 4,542,511 F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.20 to $6.98. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	4,541,511	Reported balance After 2025-01-08 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2025-01-08 · Sale · Disposed 1,000 · Balance 4,541,511
Common StockSEC Table I · non-derivative	IndirectFMR Capital, Inc.	61	Reported balance Holding disclosure · report date 2025-01-08 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 61

Filing footnotes · ownership attribution and instrument terms

F1: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.05 to $6.24. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.50 to $6.55. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.20 to $6.98. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Structure Therapeutics Inc.

Report date July 22, 2026 · Filed July 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
American Depositary SharesSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP	1,369	Reported balance After 2026-07-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-07-22 · Sale · Disposed 1,367 · Balance 1,369 F1: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
American Depositary SharesSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	16,086	Reported balance After 2026-07-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-07-22 · Sale · Disposed 16,085 · Balance 16,086 F1: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Ordinary SharesSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP	20,502	Reported balance Holding disclosure · report date 2026-07-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 20,502
Ordinary SharesSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	241,275	Reported balance Holding disclosure · report date 2026-07-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 241,275
American Depositary SharesSEC Table II · derivative / convertible security	IndirectShares held by persons and entities whose shares are subject to reporting by the undersigned	1,515,558	Reported balance Holding disclosure · report date 2026-07-22 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 1,515,558 F1: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.

F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Past disclosures · reporting ended (23)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aclaris Therapeutics, Inc.

Report date August 21, 2017 · Filed August 23, 2017

Section 16 reporting ended · disclosed 2017-08-23. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Bicara Therapeutics Inc.

Report date September 16, 2024 · Filed September 18, 2024

Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	10,818	Reported balance After 2024-09-16 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-09-16 · Conversion · Acquired 10,818 · Balance 10,818 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	723,248	Reported balance After 2024-09-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-09-16 · Conversion · Acquired 712,430 · Balance 723,248 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	1,115,333	Reported balance After 2024-09-16 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-09-16 · Conversion · Acquired 392,085 · Balance 1,115,333 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Series Seed Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	0	Reported balance After 2024-09-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-09-16 · Conversion · Disposed 10,818 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	0	Reported balance After 2024-09-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-09-16 · Conversion · Disposed 712,430 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	0	Reported balance After 2024-09-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-09-16 · Conversion · Disposed 392,085 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

Caribou Biosciences, Inc.

Report date July 27, 2021 · Filed July 29, 2021

Section 16 reporting ended · disclosed 2021-07-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	770,510	Reported balance After 2021-07-27 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-07-27 · Conversion · Acquired 770,510 · Balance 770,510 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	1,840,937	Reported balance After 2021-07-27 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-07-27 · Conversion · Acquired 1,070,427 · Balance 1,840,937 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP	17,572	Reported balance After 2021-07-27 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-07-27 · Conversion · Acquired 17,572 · Balance 17,572 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectImpresa Fund III Limited Partnership	1,464,775	Reported balance After 2021-07-27 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2021-07-27 · Conversion · Acquired 1,464,775 · Balance 1,464,775 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2021-07-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-27 · Conversion · Disposed 423,823 · Balance 0 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2021-07-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-27 · Conversion · Disposed 588,794 · Balance 0 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP	0	Reported balance After 2021-07-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-27 · Conversion · Disposed 9,666 · Balance 0 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectImpresa Fund III Limited Partnership	0	Reported balance After 2021-07-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-07-27 · Conversion · Disposed 805,707 · Balance 0 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.

Cogent Biosciences, Inc.

Report date April 03, 2018 · Filed April 05, 2018

Section 16 reporting ended · disclosed 2018-04-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	349,462	Reported balance After 2018-04-03 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-04-03 · Conversion · Acquired 349,462 · Balance 349,462 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	358,063	Reported balance After 2018-04-03 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-04-03 · Conversion · Acquired 8,601 · Balance 358,063 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	452,115	Reported balance After 2018-04-03 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2018-04-03 · Purchase · Acquired 94,052 · Balance 452,115
Common StockSEC Table I · non-derivative	IndirectImpresa Fund III Limited Partnership	1,890,701	Reported balance After 2018-04-03 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2018-04-03 · Conversion · Acquired 1,890,701 · Balance 1,890,701 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectImpresa Fund III Limited Partnership	1,937,235	Reported balance After 2018-04-03 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2018-04-03 · Conversion · Acquired 46,534 · Balance 1,937,235 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP	22,682	Reported balance After 2018-04-03 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2018-04-03 · Conversion · Acquired 22,682 · Balance 22,682 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP	23,240	Reported balance After 2018-04-03 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2018-04-03 · Conversion · Acquired 558 · Balance 23,240 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2018-04-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-04-03 · Conversion · Disposed 548,702 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectImpresa Fund III Limited Partnership	0	Reported balance After 2018-04-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-04-03 · Conversion · Disposed 2,968,650 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP	0	Reported balance After 2018-04-03 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-04-03 · Conversion · Disposed 35,614 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2018-04-03 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-04-03 · Conversion · Disposed 13,505 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectImpresa Fund III Limited Partnership	0	Reported balance After 2018-04-03 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-04-03 · Conversion · Disposed 73,065 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP	0	Reported balance After 2018-04-03 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2018-04-03 · Conversion · Disposed 877 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.

Denali Therapeutics Inc.

Report date April 09, 2018 · Filed April 11, 2018

Section 16 reporting ended · disclosed 2018-04-11. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Dimension Therapeutics, Inc.

Report date November 07, 2017 · Filed November 09, 2017

Section 16 reporting ended · disclosed 2017-11-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectImpresa Fund III Limited Partnership	Reported balance After 2017-11-07 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-11-07 · Other · Disposed 3,838,249 · Balance 0
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund III LP	Reported balance After 2017-11-07 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-11-07 · Other · Disposed 1,050,016 · Balance 0
Common StockSEC Table I · non-derivative	IndirectF-Prime Inc.	Reported balance After 2017-11-07 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-11-07 · Other · Disposed 5,057 · Balance 0

EXA CORP

Report date September 30, 2016 · Filed October 11, 2016

Section 16 reporting ended · disclosed 2016-10-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Fidelity Ventures Limited	0	Reported balance After 2016-09-30 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2016-09-30 · Gift · Disposed 2,105,642 · Balance 0

Fidelity Private Credit Fund

Report date January 29, 2024 · Filed January 31, 2024

Section 16 reporting ended · disclosed 2024-01-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class I Common Shares of Beneficial InterestSEC Table I · non-derivative	Direct	1,280,001.754	Reported balance Holding disclosure · report date 2024-01-29 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,280,001.754
Class I Common Shares of Beneficial InterestSEC Table I · non-derivative	IndirectFMR Capital Inc.	86.107	Reported balance Holding disclosure · report date 2024-01-29 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 86.107
Class I Common Shares of Beneficial InterestSEC Table I · non-derivative	IndirectFidelity Multi-Strategy Credit Fund	352,359.548	Reported balance Holding disclosure · report date 2024-01-29 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 352,359.548
Class S Common Shares of Beneficial InterestSEC Table I · non-derivative	IndirectFMR Capital Inc.	397.521	Reported balance Holding disclosure · report date 2024-01-29 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 397.521
Class D Common Shares of Beneficial InterestSEC Table I · non-derivative	IndirectFMR Capital Inc.	397.917	Reported balance Holding disclosure · report date 2024-01-29 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 397.917

Flywire Corp

Report date May 28, 2021 · Filed June 02, 2021

Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Tech Fund LP	4,183,071	Reported balance After 2021-05-28 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2021-05-28 · Conversion · Acquired 4,183,071 · Balance 4,183,071 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Tech Fund LP	5,328,597	Reported balance After 2021-05-28 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2021-05-28 · Conversion · Acquired 1,145,526 · Balance 5,328,597 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Tech Fund LP	6,829,032	Reported balance After 2021-05-28 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2021-05-28 · Conversion · Acquired 1,500,435 · Balance 6,829,032 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Tech Fund LP	7,249,056	Reported balance After 2021-05-28 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2021-05-28 · Conversion · Acquired 420,024 · Balance 7,249,056 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Tech Fund LP	7,268,490	Reported balance After 2021-05-28 transaction · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · 2021-05-28 · Conversion · Acquired 19,434 · Balance 7,268,490 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Tech Fund LP	7,460,328	Reported balance Holding disclosure · report date 2021-05-28 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 7,460,328
Series B-1 Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Tech Fund LP	0	Reported balance After 2021-05-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-05-28 · Conversion · Disposed 4,183,071 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Series B-1 NV Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Tech Fund LP	0	Reported balance After 2021-05-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-05-28 · Conversion · Disposed 1,145,526 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Tech Fund LP	0	Reported balance After 2021-05-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-05-28 · Conversion · Disposed 1,500,435 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Tech Fund LP	0	Reported balance After 2021-05-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-05-28 · Conversion · Disposed 420,024 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Tech Fund LP	0	Reported balance After 2021-05-28 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-05-28 · Conversion · Disposed 19,434 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.

KINETA, INC./DE

Report date March 13, 2017 · Filed March 15, 2017

Section 16 reporting ended · disclosed 2017-03-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	243,508	Reported balance After 2017-03-13 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-03-13 · Sale · Disposed 25,000 · Balance 243,508 F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $12.21 to $13.18. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: By Impresa Fund III Limited Partnership (238,685 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC.

Filing footnotes · ownership attribution and instrument terms

F1: By Impresa Fund III Limited Partnership (238,685 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC.

F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $12.21 to $13.18. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Mersana Therapeutics, Inc.

Report date July 03, 2017 · Filed July 06, 2017

Section 16 reporting ended · disclosed 2017-07-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund III LP	718,375	Reported balance After 2017-07-03 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-07-03 · Conversion · Acquired 718,375 · Balance 718,375 F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectccF-Prime Capital Partners Healthcare Fund III LP	1,329,981	Reported balance After 2017-07-03 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2017-07-03 · Conversion · Acquired 611,606 · Balance 1,329,981 F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock.
Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund III LP	0	Reported balance After 2017-07-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-07-03 · Conversion · Disposed 718,375 · Balance 0 F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock.
Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund III LP	0	Reported balance After 2017-07-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-07-03 · Conversion · Disposed 611,606 · Balance 0 F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund LP	383,357	Reported balance Holding disclosure · report date 2017-07-03 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 383,357
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners HC Principals Fund LP	2,597	Reported balance Holding disclosure · report date 2017-07-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,597
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2023-09-27	IndirectF-Prime Capital Partners Healthcare Fund III LP	19,126	Reported balance Holding disclosure · report date 2017-07-03 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 19,126

Filing footnotes · ownership attribution and instrument terms

F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock.

Metsera, Inc.

Report date November 13, 2025 · Filed November 17, 2025

Section 16 reporting ended · disclosed 2025-11-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Inc.	0	Reported balance After 2025-11-13 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-11-13 · Other · Disposed 3,010 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), F2: (Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectShares held by persons and entities whose shares are subject to reporting by the undersigned.	0	Reported balance After 2025-11-13 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-11-13 · Other · Disposed 2,230,450 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), F2: (Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"),

F2: (Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

Neumora Therapeutics, Inc.

Report date September 19, 2023 · Filed September 21, 2023

Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	5,387,375	Reported balance After 2023-09-19 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2023-09-19 · Conversion · Acquired 3,475,646 · Balance 5,387,375 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	5,472,340	Reported balance After 2023-09-19 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2023-09-19 · Conversion · Acquired 84,965 · Balance 5,472,340 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	1,911,729	Reported balance Holding disclosure · report date 2023-09-19 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,911,729
Common StockSEC Table I · non-derivative	IndirectF-Prime Inc.	63,724	Reported balance After 2023-09-19 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2023-09-19 · Conversion · Acquired 63,724 · Balance 63,724 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectFBRI LLC	88,289	Reported balance After 2023-09-19 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2023-09-19 · Conversion · Acquired 88,289 · Balance 88,289 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Series A-2 Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Inc.	0	Reported balance After 2023-09-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-19 · Conversion · Disposed 63,724 · Balance 0 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Series A-2 Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	0	Reported balance After 2023-09-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-19 · Conversion · Disposed 3,475,646 · Balance 0 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Fund VII LP	0	Reported balance After 2023-09-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-09-19 · Conversion · Disposed 84,965 · Balance 0 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Series A-2 Preferred StockSEC Table II · derivative / convertible security	IndirectFBRI LLC	0	Reported balance After 2023-09-19 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-09-19 · Conversion · Disposed 88,289 · Balance 0 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

Orchard Therapeutics plc

Report date March 09, 2021 · Filed March 10, 2021

Section 16 reporting ended · disclosed 2021-03-10. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

PRECISION BIOSCIENCES INC

Report date April 01, 2019 · Filed April 03, 2019

Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy F-Prime Capital Partners Healthcare Fund IV LP	3,279,170	Reported balance After 2019-04-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-04-01 · Conversion · Acquired 3,279,170 · Balance 3,279,170 F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectBy F-Prime Capital Partners Healthcare Fund IV LP	3,688,248	Reported balance After 2019-04-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-04-01 · Conversion · Acquired 409,078 · Balance 3,688,248 F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.
Common StockSEC Table I · non-derivative	IndirectBy F-Prime Capital Partners Healthcare Fund IV LP	3,738,248	Reported balance After 2019-04-01 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2019-04-01 · Purchase · Acquired 50,000 · Balance 3,738,248
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy F-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2019-04-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-04-01 · Conversion · Disposed 7,000,000 · Balance 0 F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy F-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2019-04-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-04-01 · Conversion · Disposed 873,253 · Balance 0 F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

Prime Medicine, Inc.

Report date October 24, 2022 · Filed October 26, 2022

Section 16 reporting ended · disclosed 2022-10-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	4,124,375	Reported balance After 2022-10-24 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-10-24 · Conversion · Acquired 4,124,375 · Balance 4,124,375 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP	98,967	Reported balance After 2022-10-24 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-10-24 · Conversion · Acquired 98,967 · Balance 98,967 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP	109,982	Reported balance After 2022-10-24 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-10-24 · Conversion · Acquired 11,015 · Balance 109,982 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectEntity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned	3,805,080	Reported balance After 2022-10-24 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2022-10-24 · Conversion · Acquired 3,805,080 · Balance 3,805,080 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectEntity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned	4,228,589	Reported balance After 2022-10-24 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2022-10-24 · Conversion · Acquired 423,509 · Balance 4,228,589 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Fund VI LP	0	Reported balance After 2022-10-24 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-24 · Conversion · Disposed 4,124,375 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP	0	Reported balance After 2022-10-24 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-24 · Conversion · Disposed 98,967 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP	0	Reported balance After 2022-10-24 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-24 · Conversion · Disposed 11,015 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectEntity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned	0	Reported balance After 2022-10-24 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-24 · Conversion · Disposed 3,805,080 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectEntity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned	0	Reported balance After 2022-10-24 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-10-24 · Conversion · Disposed 423,509 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

Surface Oncology, Inc.

Report date July 25, 2018 · Filed July 27, 2018

Section 16 reporting ended · disclosed 2018-07-27. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Toast, Inc.

Report date November 09, 2021 · Filed November 12, 2021

Section 16 reporting ended · disclosed 2021-11-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Common StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Tech Fund LP	6,703,780	Reported balance Holding disclosure · report date 2021-11-09 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance 6,703,780 F1: The Class B Common Stock shares are convertible on a 1-for-1 basis into the number of shares of Class A Common Stock as shown in column 3 at any time at the holder's election, and after the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The Class B Common Stock shares are convertible on a 1-for-1 basis into the number of shares of Class A Common Stock as shown in column 3 at any time at the holder's election, and after the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date.

Turnstone Biologics Corp.

Report date January 09, 2024 · Filed January 11, 2024

Section 16 reporting ended · disclosed 2024-01-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	832,652	Reported balance Holding disclosure · report date 2024-01-09 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 832,652
Common StockSEC Table I · non-derivative	IndirectImpresa Fund III Limited Partnership	296,396	Reported balance Holding disclosure · report date 2024-01-09 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 296,396
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Advisors Fund V LP	4,939	Reported balance Holding disclosure · report date 2024-01-09 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 4,939

Verve Therapeutics, Inc.

Report date July 26, 2022 · Filed July 28, 2022

Section 16 reporting ended · disclosed 2022-07-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund V LP	570,729	Reported balance Holding disclosure · report date 2022-07-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 570,729

ViewRay, Inc.

Report date August 08, 2018 · Filed August 10, 2018

Section 16 reporting ended · disclosed 2018-08-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund II LP	604,736	Reported balance After 2018-08-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-08-08 · Sale · Disposed 200,000 · Balance 604,736 F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $10.00 to $10.07. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: The general partner of F-Prime Capital Partners Healthcare Fund II LP is F-Prime Capital Partners Healthcare Advisors Fund II LP. F-Prime Capital Partners Healthcare Advisors Fund II LP is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.
Common StockSEC Table I · non-derivative	IndirectFIMM, LLC	1,620	Reported balance Holding disclosure · report date 2018-08-08 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,620 F2: FIMM, LLC is an indirect, wholly-owned subsidiary of FMR LLC.

Filing footnotes · ownership attribution and instrument terms

F1: The general partner of F-Prime Capital Partners Healthcare Fund II LP is F-Prime Capital Partners Healthcare Advisors Fund II LP. F-Prime Capital Partners Healthcare Advisors Fund II LP is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

F2: FIMM, LLC is an indirect, wholly-owned subsidiary of FMR LLC.

F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $10.00 to $10.07. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Xilio Therapeutics, Inc.

Report date October 26, 2021 · Filed October 28, 2021

Section 16 reporting ended · disclosed 2021-10-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	815,788	Reported balance After 2021-10-26 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2021-10-26 · Conversion · Acquired 789,473 · Balance 815,788 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	1,502,287	Reported balance After 2021-10-26 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2021-10-26 · Conversion · Acquired 686,499 · Balance 1,502,287 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	1,530,990	Reported balance After 2021-10-26 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2021-10-26 · Conversion · Acquired 28,703 · Balance 1,530,990 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Fund IV LP	26,315	Reported balance Holding disclosure · report date 2021-10-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 26,315
Common StockSEC Table I · non-derivative	IndirectImpresa Fund III Limited Partnership	372,215	Reported balance After 2021-10-26 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2021-10-26 · Conversion · Acquired 372,215 · Balance 372,215 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Common StockSEC Table I · non-derivative	IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP	4,465	Reported balance After 2021-10-26 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2021-10-26 · Conversion · Acquired 4,465 · Balance 4,465 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2021-10-26 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-10-26 · Conversion · Disposed 7,500,000 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2021-10-26 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-10-26 · Conversion · Disposed 6,521,739 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Fund IV LP	0	Reported balance After 2021-10-26 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-10-26 · Conversion · Disposed 272,687 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectImpresa Fund III Limited Partnership	0	Reported balance After 2021-10-26 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-10-26 · Conversion · Disposed 3,536,046 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP	0	Reported balance After 2021-10-26 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-10-26 · Conversion · Disposed 42,421 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.

Yarrow Bioscience, Inc.

Report date January 29, 2018 · Filed August 10, 2018 · Amendment

Section 16 reporting ended · disclosed 2018-08-10. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 25, 2023 Filed Jul 27, 2023 12:42 UTC	Turnstone Biologics Corp. TSBX · Entity 76646	ConversionSeries C Preferred Stock · Derivative	106,496	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-043464 · doc4.xml · derivative · entry 8 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 0 Underlying: Common Stock · 106,496 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
July 25, 2023 Filed Jul 27, 2023 12:42 UTC	Turnstone Biologics Corp. TSBX · Entity 76646	ConversionSeries D Preferred Stock · Derivative	91,663	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-043464 · doc4.xml · derivative · entry 7 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 0 Underlying: Common Stock · 91,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
July 25, 2023 Filed Jul 27, 2023 12:42 UTC	Turnstone Biologics Corp. TSBX · Entity 76646	ConversionCommon Stock	4,939	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-043464 · doc4.xml · nonDerivative · entry 6 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP Disclosed balance after: 4,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
July 25, 2023 Filed Jul 27, 2023 12:42 UTC	Turnstone Biologics Corp. TSBX · Entity 76646	ConversionCommon Stock	296,396	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-043464 · doc4.xml · nonDerivative · entry 5 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Impresa Fund III Limited Partnership Disclosed balance after: 296,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
July 25, 2023 Filed Jul 27, 2023 12:42 UTC	Turnstone Biologics Corp. TSBX · Entity 76646	ConversionCommon Stock	483,684	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-043464 · doc4.xml · nonDerivative · entry 4 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 832,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
July 25, 2023 Filed Jul 27, 2023 12:42 UTC	Turnstone Biologics Corp. TSBX · Entity 76646	ConversionCommon Stock	150,809	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-043464 · doc4.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 348,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
July 25, 2023 Filed Jul 27, 2023 12:42 UTC	Turnstone Biologics Corp. TSBX · Entity 76646	ConversionCommon Stock	106,496	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-043464 · doc4.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 198,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
July 25, 2023 Filed Jul 27, 2023 12:42 UTC	Turnstone Biologics Corp. TSBX · Entity 76646	ConversionCommon Stock	91,663	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-043464 · doc4.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 91,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
June 27, 2023 Filed Jun 29, 2023 13:48 UTC	Fidelity Private Credit Fund NONE · Entity 51131	PurchaseClass I Common Shares of Beneficial Interest	346,722.776	$25.23	$8,747,815.64	Disclosure SEC source: 0001209191-23-040138 · doc4.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Fidelity Multi-Strategy Credit Fund Disclosed balance after: 346,722.776 F1 · date: On June 1, 2023, the Reporting Person's subscription to purchase Class I Common Shares of the Issuer was accepted. On June 27, 2023, the number of shares being purchased by the Reporting Person was fixed when the purchase price per share was determined by the Issuer. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries B-1 Convertible Preferred Shares · Derivative	214,663	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 18 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 0 Underlying: Ordinary Shares · 214,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries B Convertible Preferred Shares · Derivative	414,621	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 17 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 0 Underlying: Ordinary Shares · 414,621 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries A+ Convertible Preferred Shares · Derivative	568,098	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 16 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 0 Underlying: Ordinary Shares · 568,098 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries A Convertible Preferred Shares · Derivative	3,572,022	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 15 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 0 Underlying: Ordinary Shares · 3,572,022 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries B-1 Convertible Preferred Shares · Derivative	6,947	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 14 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 0 Underlying: Ordinary Shares · 6,947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries B Convertible Preferred Shares · Derivative	7,411	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 13 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 0 Underlying: Ordinary Shares · 7,411 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries A+ Convertible Preferred Shares · Derivative	10,154	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 12 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 0 Underlying: Ordinary Shares · 10,154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries A Convertible Preferred Shares · Derivative	57,523	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 11 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 0 Underlying: Ordinary Shares · 57,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionSeries A Convertible Preferred Shares · Derivative	965,115	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · derivative · entry 10 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 0 Underlying: Ordinary Shares · 965,115 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.exercise_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. F1 · derivative.expiration_date: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	214,663	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 9 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 4,769,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	414,621	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 8 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 4,554,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	568,098	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 7 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 4,140,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	3,572,022	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 6 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 3,572,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	6,947	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 5 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 82,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	7,411	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 4 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 75,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	10,154	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 67,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	57,523	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 57,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
February 07, 2023 Filed Feb 9, 2023 19:42 UTC	Structure Therapeutics Inc. GPCR · Entity 1222	ConversionOrdinary Shares	965,115	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-23-002162 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 965,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionSeries B Convertible Preferred Stock · Derivative	423,509	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · derivative · entry 10 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 0 Underlying: Common Stock · 423,509 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionSeries A Convertible Preferred Stock · Derivative	3,805,080	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · derivative · entry 9 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 0 Underlying: Common Stock · 3,805,080 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionSeries B Convertible Preferred Stock · Derivative	11,015	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · derivative · entry 8 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 0 Underlying: Common Stock · 11,015 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionSeries A Convertible Preferred Stock · Derivative	98,967	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · derivative · entry 7 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 0 Underlying: Common Stock · 98,967 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionSeries A Convertible Preferred Stock · Derivative	4,124,375	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · derivative · entry 6 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 0 Underlying: Common Stock · 4,124,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.exercise_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. F1 · derivative.expiration_date: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionCommon Stock	423,509	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · nonDerivative · entry 5 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 4,228,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionCommon Stock	3,805,080	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · nonDerivative · entry 4 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Entity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned Disclosed balance after: 3,805,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionCommon Stock	11,015	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 109,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionCommon Stock	98,967	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 98,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
October 24, 2022 Filed Oct 26, 2022 16:23 UTC	Prime Medicine, Inc. PRME · Entity 5281	ConversionCommon Stock	4,124,375	Not disclosed	Not disclosed	Disclosure SEC source: 0000315066-22-001801 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 4,124,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. Read SEC document
September 06, 2022 Filed Sep 8, 2022 15:04 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	SaleCommon Stock	551	$54.25	$29,891.75	Disclosure SEC source: 0000315066-22-001715 · primary_doc.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Inc. Disclosed balance after: 0 Read SEC document
September 06, 2022 Filed Sep 8, 2022 15:04 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	551	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001715 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Inc. Disclosed balance after: 551 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
September 06, 2022 Filed Sep 8, 2022 15:04 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	25,620	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001715 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP Disclosed balance after: 0 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
August 05, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	SaleCommon Stock	20,159	$60.50	$1,219,619.50	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 9 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Inc. Disclosed balance after: 0 Read SEC document
August 05, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	SaleCommon Stock	167	$61.00	$10,187.00	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 8 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Impresa Fund III Limited Partnership Disclosed balance after: 0 Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	312,512	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 7 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned. Disclosed balance after: 2,803,027 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	20,159	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 6 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Inc. Disclosed balance after: 20,159 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	167,564	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 5 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP Disclosed balance after: 25,620 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	180,366	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 4 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP Disclosed balance after: 193,184 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	375,369	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Impresa Fund III Limited Partnership Disclosed balance after: 167 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	375,536	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · Impresa Fund III Limited Partnership Disclosed balance after: 375,536 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
August 04, 2022 Filed Aug 8, 2022 20:49 UTC	Beam Therapeutics Inc. BEAM · Entity 4227	OtherCommon Stock	800,000	$0.00	$0.00	Disclosure SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 2,135,511 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document
July 12, 2022 Filed Jul 14, 2022 21:24 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	63,000	$22.04	$1,388,520.00	Disclosure SEC source: 0000315066-22-001673 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 570,729 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.